

Title (en)

DIAGNOSTIC AND MEDICAMENT FOR ANALYSING THE CELL SURFACE PROTEOME OF TUMOUR AND INFLAMMATORY CELLS AND FOR TREATING TUMOROUS AND INFLAMMATORY DISEASES, PREFERABLY USING A SPECIFIC CHEMOKINE RECEPTOR ANALYSIS AND THE CHEMOKINE RECEPTOR-LIGAND INTERACTION

Title (de)

DIAGNOSTIK- UND ARZNEIMITTEL ZUR UNTERSUCHUNG DES ZELLOBERFLÄCHENPROTEOMS VON TUMOR- UND ENTZÜNDUNGSZELLEN SOWIE ZUR BEHANDLUNG VON TUMORERKRANKUNGEN UND ENTZÜNDLICHEN ERKRANKUNGEN VORZUGSWEISE MIT HILFE EINER SPEZIFISCHEN CHEMOKINREZEPTOR-ANALYSE UND DER CHEMOKINREZEPTOR-LIGAND-INTERAKTION

Title (fr)

MEDICAMENT ET MOYEN DIAGNOSTIQUE POUR ANALYSER LE PROTEOME DE SURFACE DE CELLULES TUMORALES ET INFLAMMATOIRES, ET POUR TRAITER DES MALADIES TUMORALES ET INFLAMMATOIRES, DE PREFERENCE AU MOYEN D'UNE ANALYSE SPECIFIQUE DES RECEPTEURS DE CHIMIOKINES ET DE L'INTERACTION DE LIGANDS RECEPTEURS DE CHIMIOKI

Publication

EP 1268554 A2 20030102 (DE)

Application

EP 01923710 A 20010402

Priority

- DE 10016013 A 20000331
- EP 0103708 W 20010402

Abstract (en)

[origin: WO0172830A2] The invention relates to the production of a medicament and a diagnostic agent, obtained by a proteome analysis, preferably containing at least two different chemokine receptor ligands or chemokine receptor antibodies and in addition, to the use of at least two different chemokine receptor ligands, chemokine receptor antibodies and/or two different chemokine receptors. The medicament preferably contains as inhibitors, ligands or antibodies of at least two chemokine receptors or of the related algorithms of the surface chemokine receptor proteome. The invention also relates to at least one chemokine receptor ligand and/or a chemokine receptor, peptides and antibodies and to the use of the same for diagnosing and treating tumorous and inflammatory diseases. Similarly, clusters of analysed tumour cell surface proteomes, such as ectoproteases, adhesion molecules or different receptor types can be used. The invention relates to a method for diagnostic and therapeutic purposes and for the medicinal and commercial use of chemokines and their corresponding receptors and their antagonists including antibodies, for inhibiting cancer growth and its metastatic spread and for repressing inflammatory and auto-immune diseases. The method is based on the finding that chemokines act on specific tumour and inflammatory cells in an autocrine, paracrine and endocrine manner by means of the disease-specific constellation of chemokine receptor proteome. Primary and secondary tumours and specific inflammatory cells are controlled in their migration and proliferation behaviour. The diagnostic detection of a local increase in expressed and regulated chemokines and of the presence of the chemokine receptor compositions allows the significant repression or complete prevention of cancer growth, tumour metastatic spread and both inflammatory and auto-immune diseases.

IPC 1-7

C07K 16/28

IPC 8 full level

A61K 39/395 (2006.01); **A61K 45/00** (2006.01); **A61P 1/00** (2006.01); **A61P 5/00** (2006.01); **A61P 9/00** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 13/00** (2006.01); **A61P 13/12** (2006.01); **A61P 17/00** (2006.01); **A61P 19/02** (2006.01); **A61P 21/00** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C07K 14/52** (2006.01); **C07K 16/28** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/68** (2006.01); **G01N 33/53** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP US)

A61P 1/00 (2017.12 - EP); **A61P 5/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 14/522** (2013.01 - EP US); **C07K 16/2866** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US)

Citation (search report)

See references of WO 0172830A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0172830 A2 20011004; **WO 0172830 A3 20020620**; AU 5041201 A 20011008; EP 1268554 A2 20030102; JP 2003530325 A 20031014; US 2003186889 A1 20031002

DOCDB simple family (application)

EP 0103708 W 20010402; AU 5041201 A 20010402; EP 01923710 A 20010402; JP 2001571761 A 20010402; US 23942302 A 20020923